Questions about this study?
The HopeStage team will email you.
TerminatedNCT06514742
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
This study evaluates the safety and effectiveness of Aticaprant for people with depression.
Medication studyAges 18–64Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of Aticaprant for people with depression.
Who could participate?
Listed age limits: 18 years to 64 years.
- Listed locations
- Huntsville, United States · Phoenix, United States and 71 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 26, 2024
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 101
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Belgium, Brazil, ...
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT06514742
- Official title
Show the full official title
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open Label Long-term Extension Treatment With Aticaprant
Recruitment & locations
TerminatedHuntsville, United States · Phoenix, United States · Tucson, United States
70 more locations
- Anaheim, United States
- Bellflower, United States
- Glendale, United States
- Imperial, United States
- Orange, United States
- San Jose, United States
- Temecula, United States
- Walnut Creek, United States
- Colorado Springs, United States
- Aventura, United States
- Boca Raton, United States
- Fort Myers, United States
- Hialeah, United States
- Miami, United States
- Miami Lakes, United States
- Pembroke Pines, United States
- Tampa, United States
- West Palm Beach, United States
- Peachtree Corners, United States
- Springfield, United States
- New Orleans, United States
- Gaithersburg, United States
- Brooklyn, United States
- New York, United States
- Charlotte, United States
- Cincinnati, United States
- Columbus, United States
- Edmond, United States
- Media, United States
- Houston, United States
- McKinney, United States
- Richmond, United States
- Bellevue, United States
- Alken, Belgium
- La Louvière, Belgium
- Liège, Belgium
- Mechelen, Belgium
- Fortaleza, Brazil
- Porto Alegre, Brazil
- São Bernardo do Campo, Brazil
- São Paulo, Brazil
- Burgas, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Helsinki, Finland
- Kuopio, Finland
- Oulu, Finland
- Tampere, Finland
- Turku, Finland
- Budapest, Hungary
- Gyöngyös, Hungary
- Győr, Hungary
- Kalocsa, Hungary
- Pécs, Hungary
- Szekszárd, Hungary
- Bydgoszcz, Poland
- Gdansk, Poland
- Torun, Poland
- Wroclaw, Poland
- Barcelona, Spain
- Madrid, Spain
- Oviedo, Spain
- Sabadell, Spain
- Seville, Spain
- Vigo, Spain
- Zamora, Spain
- Halmstad, Sweden
- Linköping, Sweden
- Lund, Sweden
- Stockholm, Sweden
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of Aticaprant for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Does this study involve medication?
Yes. The study involves medication, including Aticaprant.
Who can participate?
Listed age limits: 18 years to 64 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepr...